Decision on IPR: Mar 13, 2019
|
AIA Review
|
Filing Date
|
Institution Date
|
Petitioner
|
US Patent
|
Respondent
|
Final Written Decision
|
|
IPR2017-02131
|
09/19/2017
|
03/22/2018
|
Merck
|
9,492,559
|
Pfizer Inc.
|
claims 1–10, 16–19, & 38–45 are unpatentable
|
|
IPR2017-02132
|
09/19/2017
|
03/22/2018
|
Merck
|
9,492,559
|
Pfizer Inc.
|
claims 1–10, 16–19, and 38–45 are unpatentable
|
|
IPR2017-02136
|
09/19/2017
|
03/22/2018
|
Merck
|
9,492,559
|
Pfizer Inc.
|
claims 11–15 and 20–37 are unpatentable
|
|
IPR2017-02138
|
09/19/2017
|
03/22/2018
|
Merck
|
9,492,559
|
Pfizer Inc.
|
claims 11–15 and 20–37 are unpatentable
|
Previously Merck also filed other IPRs (IPR2018-00187 & IPR2018-00188) on 11/20/2017 of which IPR’187 was instituted & IPR’188 was denied by PTAB.
US 9,492,559 (Pfizer Inc.; Exp: Jan 15, 2035) :
1. An immunogenic composition comprising a Streptococcus pneumoniae serotype 22F glycoconjugate, wherein the glycoconjugate has a molecular weight of between 1000 kDa and 12,500 kDa and comprises an isolated capsular polysaccharide from S. pneumoniae serotype 22F and a carrier protein, and wherein a ratio (w/w) of the polysaccharide to the carrier protein is between 0.4 and 2.
Leave a Reply